PanOptica has completed $11 million in Series B financing to clinically advance PAN-90806, its small molecule anti-VEGF eye drop for treating neovascular eye diseases, according to a press release.
The funding, provided by Third Rock Ventures and SV Health Investors, will allow the company to proceed with a phase 1/2 study of PAN-90806 as monotherapy for treatment of neovascular age-related macular degeneration.
“The additional Series B financing reflects our investors’ confidence in the potential of our new advanced-generation formulation of topical PAN-90806 and the direction of
Uncategorized